相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dose fractionation of CAR-T cells. A systematic review of clinical outcomes
Matthew Frigault et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)
Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
Michael Rainone et al.
BLOOD ADVANCES (2023)
Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy
Sammita Satyanarayan et al.
NEUROHOSPITALIST (2023)
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Melissa R. Hines et al.
TRANSPLANTATION AND CELLULAR THERAPY (2023)
Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions
Jeanette Wat et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
Marc Wehrli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*
Cristina Gutierrez et al.
CRITICAL CARE MEDICINE (2022)
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
Kai Rejeski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
Caroline Diorio et al.
BLOOD ADVANCES (2022)
Dose-response correlation for CAR-T cells: a systematic review of clinical studies
Anand Rotte et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Renata Ursu et al.
NEUROLOGY (2022)
The use of ICU resources in CAR-T cell recipients: a hospital-wide study
Sandrine Valade et al.
ANNALS OF INTENSIVE CARE (2022)
Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
Seema Patel et al.
BLOOD (2022)
The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
Kai Rejeski et al.
BLOOD (2022)
The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
Kai Rejeski et al.
BLOOD (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity
Andrea Schmidts et al.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 (2021)
A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
Jae H. Park et al.
BLOOD (2021)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Max S. Topp et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy
Jing Pan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D. Santomasso et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
John H. Baird et al.
BLOOD ADVANCES (2021)
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
Di Wang et al.
BLOOD CANCER JOURNAL (2021)
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
Ying Wang et al.
BLOOD ADVANCES (2021)
Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma
Vanessa E. Kennedy et al.
BLOOD ADVANCES (2021)
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
Élie Azoulay et al.
Lancet Haematology (2021)
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski et al.
BLOOD (2021)
Characterization of HLH-like manifestations as a CRS variant in CD22 CAR T cells
Daniel A. Lichtenstein et al.
BLOOD (2021)
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Olalekan O. Oluwole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
Jingshi Wang et al.
HAEMATOLOGICA (2020)
Intrathecal Chemotherapy: An Alternative Treatment Strategy to Prolonged Corticosteroids for Severe CAR T Associated Neurotoxicity
Filiz Yucebay et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
Robert David Sandler et al.
FRONTIERS IN IMMUNOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
Eugenio Galli et al.
BONE MARROW TRANSPLANTATION (2020)
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
Kitsada Wudhikarn et al.
BLOOD ADVANCES (2020)
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Paolo Strati et al.
BLOOD ADVANCES (2020)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis
Avirup Guha et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
Kitsada Wudhikarn et al.
BLOOD CANCER JOURNAL (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela Maus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know
Lorna Neill et al.
PRACTICAL NEUROLOGY (2020)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Bradley D. Hunter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy
Joshua A. Hill et al.
BLOOD REVIEWS (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Pharmacologic control of CAR-T cell function using dasatinib
Evan W. Weber et al.
BLOOD ADVANCES (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Noelle Frey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis
Larisa Broglie et al.
BLOOD ADVANCES (2017)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Marieke Griffioen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)